Your browser doesn't support javascript.
loading
Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
Parren, Paul W H I; Burton, Dennis R; Bradbury, Andrew; Huston, James S; Carter, Paul J; Veldman, Trudi; Chester, Kerry A; Larrick, James W; Alfenito, Mark R; Scott, Jamie K; Weiner, Louis M; Adams, Gregory P; Reichert, Janice M.
Afiliación
  • Parren PW; a Genmab; Utrecht, the Netherlands and Leiden University Medical Center ; Leiden , the Netherlands.
  • Burton DR; b The Scripps Research Institute ; La Jolla , CA USA.
  • Bradbury A; c Los Alamos National Laboratory ; Los Alamos , NM USA.
  • Huston JS; d Huston BioConsulting, LLC ; Newton Lower Falls , MA USA.
  • Carter PJ; e Genentech, Inc.. ; South San Francisco , CA USA.
  • Veldman T; f AbbVie ; Worcester , MA USA.
  • Chester KA; g University College London ; London , UK.
  • Larrick JW; h Panorama Research Institute and Velocity Pharmaceutical Development ; South San Francisco , CA USA.
  • Alfenito MR; i EnGen Bio, Inc.. ; San Mateo , CA USA.
  • Scott JK; j Simon Fraser University ; Burnaby , BC Canada.
  • Weiner LM; k Georgetown University Medical Center ; Washington, DC USA.
  • Adams GP; l Viventia Bio, Inc.. ; Philadelphia , PA USA.
  • Reichert JM; m Reichert Biotechnology Consulting LLC ; Framingham , MA USA.
MAbs ; 7(6): 981-8, 2015.
Article en En | MEDLINE | ID: mdl-26421752
Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society, will be held in San Diego, CA in early December 2015. In this meeting preview, the chairs provide their thoughts on the importance of their session topics, which include antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, overcoming resistance to clinical immunotherapy, and building comprehensive IGVH-gene repertoires through discovering, confirming and cataloging new germline IGVH genes. The Antibody Society's special session will focus on "Antibodies to watch" in 2016, which are a subset of the nearly 50 antibodies currently in Phase 3 clinical studies. Featuring over 100 speakers in total, the meeting will commence with keynote presentations by Erica Ollmann Saphire (The Scripps Research Institute), Wayne A. Marasco (Dana-Farber Cancer Institute/Harvard Medical School), Joe W. Gray (Oregon Health & Science University), and Anna M. Wu (University of California Los Angeles), and it will conclude with workshops on the promise and challenges of using next-generation sequencing for antibody discovery and engineering from synthetic and in vivo libraries and on computational antibody design.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ingeniería de Proteínas / Anticuerpos Biespecíficos / Inmunoconjugados / Anticuerpos Monoclonales Límite: Humans Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2015 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ingeniería de Proteínas / Anticuerpos Biespecíficos / Inmunoconjugados / Anticuerpos Monoclonales Límite: Humans Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2015 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos